Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Epigenetic clock analysis of diet, exercise, education, and lifestyle factors.

Quach A, Levine ME, Tanaka T, Lu AT, Chen BH, Ferrucci L, Ritz B, Bandinelli S, Neuhouser ML, Beasley JM, Snetselaar L, Wallace RB, Tsao PS, Absher D, Assimes TL, Stewart JD, Li Y, Hou L, Baccarelli AA, Whitsel EA, Horvath S.

Aging (Albany NY). 2017 Feb 14;9(2):419-446. doi: 10.18632/aging.101168.

3.

Therapeutic modification of arterial stiffness: An update and comprehensive review.

Wu CF, Liu PY, Wu TJ, Hung Y, Yang SP, Lin GM.

World J Cardiol. 2015 Nov 26;7(11):742-53. doi: 10.4330/wjc.v7.i11.742. Review.

4.

Obesity, metabolic syndrome, and airway disease: a bioenergetic problem?

Agrawal A, Prakash YS.

Immunol Allergy Clin North Am. 2014 Nov;34(4):785-96. doi: 10.1016/j.iac.2014.07.004. Epub 2014 Aug 21. Review.

5.

Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Vassilatou E.

World J Gastroenterol. 2014 Jul 14;20(26):8351-63. doi: 10.3748/wjg.v20.i26.8351. Review.

6.

What do we know about metabolic syndrome in adolescents with PCOS?

Cırık DA, Dilbaz B.

J Turk Ger Gynecol Assoc. 2014 Mar 1;15(1):49-55. doi: 10.5152/jtgga.2014.95776. eCollection 2014. Review.

7.

Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.

Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB; Diabetes Prevention Program Research Group.

Diabetes Obes Metab. 2014 Apr;16(4):326-33. doi: 10.1111/dom.12220. Epub 2013 Oct 29.

8.

Longterm management of Polycystic Ovarian Syndrome (PCOS).

Bates GW, Legro RS.

Mol Cell Endocrinol. 2013 Jul 5;373(1-2):91-7. doi: 10.1016/j.mce.2012.10.029. Epub 2012 Dec 20. Review.

9.

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

Van Wagner LB, Rinella ME.

Therap Adv Gastroenterol. 2011 Jul;4(4):249-63. doi: 10.1177/1756283X11403809.

10.

AMP-activated protein kinase and metabolic control.

Viollet B, Andreelli F.

Handb Exp Pharmacol. 2011;(203):303-30. doi: 10.1007/978-3-642-17214-4_13. Review.

11.

Treatment options for polycystic ovary syndrome.

Badawy A, Elnashar A.

Int J Womens Health. 2011 Feb 8;3:25-35. doi: 10.2147/IJWH.S11304.

12.

Advances in the treatment of nonalcoholic fatty liver disease.

Mehta SR.

Ther Adv Endocrinol Metab. 2010 Jun;1(3):101-15. doi: 10.1177/2042018810379587.

13.

Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.

Gupta AK, Smith SR, Greenway FL, Bray GA.

Diabetes Obes Metab. 2009 Apr;11(4):330-7. doi: 10.1111/j.1463-1326.2008.00965.x.

14.

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.

Ann Intern Med. 2005 Apr 19;142(8):611-9.

15.

Metformin in polycystic ovary syndrome: systematic review and meta-analysis.

Lord JM, Flight IH, Norman RJ.

BMJ. 2003 Oct 25;327(7421):951-3. Review.

Supplemental Content

Loading ...
Support Center